SURVYR

KMTS

Kestra Medical Technologies, Ltd.
$29.87
−$0.12 (0.40%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-36%-23%-11%+2%+15%Oct 2025Oct 2026Apr 202652w high $30.0052w low $17.34
KMTSSPY
Wall St. Highest PT $34.00 (+13.8%) Wall St. Avg PT $30.75 (+2.9%)
$18$22$26$31$35POC $27Hi $34Avg $31
Underwater Drawdown %Max DD -36.2%Current -0.4%
0.0%-36.2%
Relative Strength vs SPY-3.6% vs SPYUnderperforming
+48%0%-48%
1W
+$2.56 (9.37%)
1M
+$1.74 (6.19%)
3M
+$7.12 (31.30%)
6M
+$10.36 (53.10%)
YTD
+$3.35 (12.63%)
1Y
+$1.92 (6.87%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
9 analysts · mean score 1.44
1 = Strong Buy · 5 = Sell
Strong Buy222%
Buy667%
Hold111%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$29.87
Average target$30.75
+$0.88 (+2.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$28.00
Median$30.00
High$34.00
12-month Wall Street target range
Recent analyst rating changes · 21
Initiated
2026-10-20 · Evercore ISI Group started covering KMTS at Outperform
Reiterated
2026-09-15 · BTIG reiterated Buy on KMTS
Reiterated
2026-09-02 · BTIG reiterated Buy on KMTS
Initiated
2026-08-10 · JP Morgan started covering KMTS at Overweight
Initiated
2026-07-21 · Oppenheimer started covering KMTS at Perform
Reiterated
2026-07-15 · BTIG reiterated Buy on KMTS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.7B
P/E (next 12 months, estimated)-14.0
52-week range$17.34 – $30.00
Revenue growth (latest quarter vs a year ago)+59.9%
Dividend yieldNo dividend
Analyst consensusStrong Buy (8)
Average analyst price target$30.75 (+3%)

What they do

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform.

Healthcare · Medical Instruments & Supplies
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for KMTS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

KMTS earningsNext report in 47 days
Next report
Mon Dec 14, 2026Time not confirmed
EPS consensus-$0.60 range -$0.61–-$0.60
Revenue consensus$32.1M 9 analysts
Last 4 quarters · EPS vs estimate
Sep 14, 2026-$0.46est -$0.62+26.7%Above estimates
Jul 14, 2026-$0.49est -$0.58+15.8%Above estimates
Mar 17, 2026-$0.40est -$0.60+32.6%Above estimates
Dec 11, 2025-$0.45est -$0.56+19.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 12:14:45 ET
25-0425-0725-0925-1226-0326-0726-09-1.180.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-07-31$31.0M+59.9%
2026-04-30$28.6M–
2026-01-31$24.6M–
2025-10-31$22.6M–
2025-07-31$19.4M–

News & catalysts

More news
Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
GlobeNewswire · Oct 01
Kestra Medical Technologies (KMTS) Could Be 17% Undervalued Following Raised Revenue Outlook
Simply Wall St. · Sep 21
Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?
Insider Monkey · Sep 17
Kestra (KMTS) Q1 2027 Earnings Call Transcript
Motley Fool · Sep 15
KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 2027 Earnings Call Summary
Moby · Sep 15
Rating changes
Initiated
2026-10-20 · Evercore ISI Group started covering KMTS at Outperform
Reiterated
2026-09-15 · BTIG reiterated Buy on KMTS
Reiterated
2026-09-02 · BTIG reiterated Buy on KMTS
Initiated
2026-08-10 · JP Morgan started covering KMTS at Overweight
Initiated
2026-07-21 · Oppenheimer started covering KMTS at Perform
Reiterated
2026-07-15 · BTIG reiterated Buy on KMTS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Umberger Traci S
Director, See Remarks · 2026-10-21
Sell
$101.0K
Umberger Traci S
Director, See Remarks · 2026-10-21
Sell
$2.6M
Webster Brian Daniel
Director, See Remarks · 2026-10-20
Sell
$50.3K
Webster Brian Daniel
Director, See Remarks · 2026-10-20
Sell
$393.1K
Cohen Raymond W
Director · 2026-09-30
Sell
$97.5K
Kwo Elizabeth
Director · 2026-09-21
Sell
$97.3K
Ladone Mary Kay
Director · 2026-09-08
Sell
$98.5K
Reilly Kevin C
Director · 2026-09-08
Sell
$73.7K
Hanley Conor
Director · 2026-09-08
Sell
$143.8K
Schwartz Jeffrey Lawrence
Director, 10% owner · 2026-09-08
Sell
$97.9K
Webster Brian Daniel
Director, See Remarks · 2026-08-17
Sell
$412.2K
Mahboob Vaseem
Chief Financial Officer · 2026-08-07
Sell
$13.2K

Stats refreshed 2026-10-25 12:14:45 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026